FRED HUTCH

fredhutch.org/HICOR

HICOR

HUTCHINSON INSTITUTE FOR CANCER OUTCOMES RESEARCH

The Cancer Policy Research Affinity Group (CPRAG) &
The Hutchinson Institute for Cancer Outcomes Research
Present:

Women Preferences for and Cost-Effectiveness Analyses of Single Nucleotide Polymorphism Gene Testing in Breast Cancer Screening

---

In this presentation, I will take the audience through three recent pieces of work. The first piece is a systematic review on the current evidence for the diagnostic properties of Single Nucleotide Polymorphism (SNP) gene testing. The second piece is a discrete choice experiment in which we asked Singaporean women for their preferences and willingness to pay for SNP gene testing for breast cancer screening. The third piece is a cost-effectiveness analysis of incorporating SNP gene testing in breast cancer screening programmes performed from the US health system perspective.

---

with Wee Hwee Lin, PhD

Dr. Wee Hwee Lin obtained her BSc(Pharm)(Hons) and PhD from the Department of Pharmacy, National University of Singapore (NUS), in 2001 and 2006, respectively. She is currently an Assistant Professor in the same Department and a joint Assistant Professor at the Saw Swee Hock School of Public Health, NUS. She seeks to inform policy making through translational research with active engagement of the stakeholders including clinicians, patients and policy makers. In 2011, Dr. Wee received the International Society for Quality of Life Research (ISOQOL) Young Investigator Award. In addition, she served as an elected member of the Board of Directors of ISOQOL from 2013-2015. She was also an associate editor of Health and Quality of Life Outcomes (2012 – 2016), a BMC journal on health-related quality of life.

Dr. Wee's research encompasses health-related quality of life, cost-effectiveness analyses, patient preferences and medication adherence. Her current work involves understanding patient preferences for alternative high cost cancer treatments, women's preferences for gene testing for non-familial breast cancer risk and value of high cost therapy from patient's perspective. She is currently a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Personalized Medicine Working Group.

Tuesday, April 11, 2017 | 10:00-11:00 am
Fred Hutch, Arnold Building, M4-A805/817
Light Refreshments Provided

For more information, please contact Caleb Richmond | cnrichmo@fredhutch.org | 206.667.3701